IQVIA's new white paper maps how digital health technologies can reshape CNS clinical trial endpoints

IQVIA released the second installment of its digital health technology white paper series on July 14, 2026, this time focused squarely on central nervous system clinical trials. The paper offers clinical operations leaders and trial design teams a structured methodology for selecting, developing, and validating digital endpoints, addressing one of the most persistent measurement problems in drug development.

Why CNS trials are the proving ground for digital endpoints

CNS drug development has long struggled with measurement. Traditional clinical outcome assessments (COAs) in conditions like Alzheimer's disease, Parkinson's disease, and major depressive disorder depend heavily on clinician ratings or patient recall, both of which introduce variability that can obscure real treatment effects or produce false signals. Rater training, assessment frequency, and patient reporting fatigue all compound the problem.

Digital health technologies (DHTs) offer a different approach. According to the IQVIA white paper, sensors, software platforms, and connected devices can generate continuous, objective data streams that capture how patients actually function between clinic visits. That shift from episodic to continuous measurement is operationally significant for sponsors designing pivotal studies.

The paper positions DHT-derived data not as a replacement for all existing assessments but as a complement, or in some cases an enhancement, to established COA frameworks. That framing matters for regulatory strategy: FDA and EMA have both issued guidance on DHTs in recent years, and sponsors need to demonstrate that any new digital measure meets the evidentiary bar for its intended context of use.

Three operational use cases for CNS DHT endpoints

The white paper structures its guidance around three practical applications that clinical teams are most likely to encounter when evaluating DHTs for CNS programs.

• Functional outcomes: Wearable and passive sensor data can track real-world motor function, activity levels, and daily living performance, capturing dimensions of CNS disease that structured clinical scales may miss or measure only coarsely.
• Symptom monitoring: Continuous data collection between visits enables detection of fluctuation patterns in mood, sleep, cognition, or motor behavior that a single clinic assessment cannot reflect. This is particularly relevant in episodic conditions like bipolar disorder or trials targeting prodromal stages of neurodegenerative disease.
• Population stratification: Digital biomarkers derived from sensor data can help identify patient subgroups that are more likely to respond to a given therapy, sharpening enrollment criteria and potentially reducing trial size requirements.

Each of these use cases carries distinct validation requirements. A digital measure used purely for enrichment has a different evidentiary burden than one proposed as a primary or co-primary endpoint in a registration trial. The IQVIA framework addresses that distinction directly, according to the white paper summary.

The validation pathway clinical teams need to plan for

One of the most operationally relevant aspects of the paper is its guidance on validation. Regulatory acceptance of a digital endpoint depends on demonstrating that the measure is technically reliable, that it captures something meaningful to patients, and that it behaves predictably across the populations and conditions where it will be used. Those steps take time and require deliberate planning well before a Phase 2 or Phase 3 protocol is locked.

IQVIA frames this as a development and validation pathway, echoing the terminology regulators have used in their own DHT guidance documents. For clinical operations leaders, the practical implication is straightforward: teams that begin DHT validation concurrently with early-phase studies are better positioned to use digital endpoints in later, higher-stakes trials. Teams that wait until a Phase 3 design is underway often find that validation evidence is insufficient for regulatory acceptance.

The paper also addresses patient centricity as a design criterion, not just a communication goal. A digital endpoint that burdens patients with complex device interactions or that requires frequent charging and syncing will see poor adherence, which undermines data quality regardless of how technically sound the sensor is. Usability testing and patient input are part of the validation chain, according to IQVIA's framework.

What this means for your team

• Audit your CNS pipeline for trials that still rely exclusively on traditional rater scales and evaluate whether DHT-derived measures could reduce rater variability or capture continuous symptom data that existing assessments miss.
• Map DHT validation timelines against your current phase progression. If a program is in Phase 1 or early Phase 2, there may still be a window to generate the validation evidence regulators will expect before a registration trial.
• Evaluate device and software vendor qualification early. The credibility of a digital endpoint depends partly on the technical validation of the underlying hardware and software, not just the clinical data it generates.
• Engage patient advocacy or advisory panels in usability testing for any wearable or app-based DHT. Poor device adherence in later-phase trials is difficult to recover from statistically.